MARKET

CORT

CORT

Corcept Therapeutics Inc
NASDAQ
87.08
+2.33
+2.74%
Opening 10:27 06/26 EDT
OPEN
83.72
PREV CLOSE
84.75
HIGH
87.33
LOW
82.54
VOLUME
112.43K
TURNOVER
--
52 WEEK HIGH
91.00
52 WEEK LOW
28.66
MARKET CAP
9.35B
P/E (TTM)
245.49
1D
5D
1M
3M
1Y
5Y
1D
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
PR Newswire · 15h ago
3 Unpopular Stocks We Steer Clear Of
Barchart · 3d ago
Weekly Report: what happened at CORT last week (0615-0619)?
Weekly Report · 4d ago
Corcept Therapeutics Rocked by Major Insider Stock Sale
TipRanks · 06/19 02:03
Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million
PUBT · 06/18 20:31
Corcept Resubmits FDA Application for Relacorilant in Cushing’s
TipRanks · 06/17 22:11
Corcept resubmits relacorilant NDA for Cushing’s syndrome
Seeking Alpha · 06/17 20:47
Corcept Resubmits FDA Application for Cushing Syndrome Drug
Dow Jones · 06/17 20:43
More
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.

Webull offers Corcept Therapeutics Inc stock information, including NASDAQ: CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.